Patents Assigned to AstraZeneca
  • Crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a] pyridine-6-carboxamide mesylate salt
    Patent number: 7459463
    Abstract: The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6 -dimethylbenzylamino)-N-hydroxyethyl-imidazo[1,2-a]pyridine-6-carboxamide mesylate salt and to mixture thereof. Further, the present invention also relates to processes for obtaining them, the use of said compounds for the treatment of gastrointestinal disorders, and pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: December 2, 2008
    Assignee: AstraZeneca AB
    Inventors: Lars Lilljequist, Maria Lindkvist, Peter Nordberg, Ursula Pettersson, Tesfai Sebhatu
  • Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies
    Publication number: 20080293709
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 13, 2006
    Publication date: November 27, 2008
    Applicant: AstraZeneca AB
    Inventors: Jeffrey Albert, Gianni Chessari, Miles Stuart Congreve, Phil Edwards, Christopher Murray, Sahil Patel, Mark Sylvester
  • Novel 2-Amino-Imidazole-4-One Compounds and Their Use in the Manufacture of a Medicament to Be Used in the Treatment of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration and Dementia
    Publication number: 20080293718
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 20, 2006
    Publication date: November 27, 2008
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Stefan Berg, Jeremy Burrows, Gianni Chessari, Miles Stuart Congreve, Johan Hedstrom, Sven Hellberg, Katharina Hogdin, Jacob Kihlstrom, Karin Kolmodin, Johan Lindstrom, Christopher Murray, Sahil Patel
  • Thioxanthine Derivatives as Myeloperoxidase Inhibitors
    Publication number: 20080293748
    Abstract: There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.
    Type: Application
    Filed: August 4, 2008
    Publication date: November 27, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Sverker Hanson, Gunnar Nordvall, Anna-Karin Tiden
  • Delivery Device
    Publication number: 20080289653
    Abstract: A delivery device for administering particulate medicaments, such as dry powder. The delivery device comprises a body and a flow path comprising a chamber with an inlet and an outlet for the stream of air. The chamber is rotatable in relation to the body. Dislodging means are arranged in contact with the inner surface of the chamber. The dislodging means and the chamber are relatively rotatable in relation to one another, such that the inside of the chamber is cleaned by the dislodging means when the dislodging means and the chamber are rotated in relation to one another.
    Type: Application
    Filed: December 21, 2006
    Publication date: November 27, 2008
    Applicant: ASTRAZENECA AB
    Inventor: Allan Dagsland
  • Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer
    Publication number: 20080293744
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: August 16, 2005
    Publication date: November 27, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Timothy Pontz, Daniel John Russell, Marie-Elena Theoclitou, XiaoLan Zheng
  • Novel Hydantoin Derivatives as Metalloproteinase Inhibitors
    Publication number: 20080293743
    Abstract: The invention provides compounds of formula (I): wherein R1, R2, A, A1 and B are as defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy. The compounds are useful as MMP inhibitors.
    Type: Application
    Filed: December 14, 2005
    Publication date: November 27, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Balint Gabos, Michael Lundkvist, Magnus Munck Af Rosenschold, Igor Shamovsky, Pavol Zlatoidsky
  • Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
    Publication number: 20080293775
    Abstract: The invention relates to substituted diphenylethers, -amines, -sulfides, and -methanes as useful pharmaceutical compounds for treating respiratory-disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Application
    Filed: December 12, 2006
    Publication date: November 27, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Roger Victor Bonnert, Andrew Cook, Timothy Jon Luker, Rukhsana Tasneem Mohammed, Stephen Thom
  • Formulation
    Patent number: 7456160
    Abstract: The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7?-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17?-diol, more particularly to a formulation adapted for administration by injection containing the compound 7?-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17?-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
    Type: Grant
    Filed: June 22, 2004
    Date of Patent: November 25, 2008
    Assignee: AstraZeneca AB
    Inventors: John R Evans, Rosalind U Grundy
  • Compounds
    Patent number: 7456200
    Abstract: The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing compounds of the formula I and to the use of compounds of the formula I in therapy.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: November 25, 2008
    Assignee: Astrazeneca AB
    Inventors: Jalaj Arora, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tomislav Stefanac, Thomas M. Stormann, David Wensbo, Tao Xin, Helena Gyback, Martin Johansson, Annika Kers, John Malmberg, Alexander Minidis, Karin Oscarsson, Mangus Waldman, Ulrika Yngve, Christoffer Osterwall
  • Substituted Aminopyridines and Uses Thereof
    Publication number: 20080287399
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: December 12, 2005
    Publication date: November 20, 2008
    Applicant: AstraZeneca AB
    Inventors: Jeffrey Scott Albert, Owen Callaghan, James Campbell, Robin Arthur Ellis Carr, Gianni Chessari, Suzanna Cowan, Miles Stuart Congreve, Phil Edwards, Martyn Frederickson, Christopher William Murray, Sahil Patel
  • Alkylpyridyl Quinolines as Nk3 Receptor Modulators
    Publication number: 20080287492
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and p are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: August 9, 2006
    Publication date: November 20, 2008
    Applicant: AstraZeneca AB
    Inventors: Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li
  • Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
    Publication number: 20080287437
    Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Application
    Filed: May 12, 2006
    Publication date: November 20, 2008
    Applicant: AstraZeneca AB
    Inventors: Bin Wang, Tao Wang
  • Extended Release Compositions and Methods for Their Manufacture
    Publication number: 20080287418
    Abstract: Extended release formulations of quetiapine and its pharmaceutically salts, and methods for manufacture of the formulations, may include the use of polymers selected for their physical and chemical characteristics. The formulations may include polymers selected to cause solid dosage forms of the formulations to conform to preselected quetiapine release criteria. The formulations may include non-polymer materials that may affect quetiapine release.
    Type: Application
    Filed: November 14, 2007
    Publication date: November 20, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Daniel Brown, Donna Caster, Brian Clark, Sandra Hopkins, Jennifer Llewelyn, Elizabeth Meehan, Lisa Martin, Robert Timko, Husheng Yang
  • Method to predict or monitor the response of a patient to an erbb receptor drug
    Publication number: 20080286785
    Abstract: The invention provides a method of detecting ErbB receptor mutations comprising the steps of providing a bio-fluid sample from a patient; extracting DNA from said sample; and screening said DNA for the presence of one or more mutations that alter tyrosine kinase activity in the receptor.
    Type: Application
    Filed: April 7, 2008
    Publication date: November 20, 2008
    Applicant: AstraZeneca UK Limited
    Inventors: Kazuto Nishio, Hideharu Kimura, Kazuo Kasahara
  • NEW COMPOUNDS 834
    Publication number: 20080287462
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: May 15, 2008
    Publication date: November 20, 2008
    Applicants: AstraZeneca AB, Astex Therapeutics Limited
    Inventors: Gianni Chessari, Miles Stuart Congreve, Jorg Holenz, Christopher Murray, Sahil Patel, Laszlo Rakos, Didier Rotticci
  • 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer
    Publication number: 20080287475
    Abstract: This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Application
    Filed: October 26, 2006
    Publication date: November 20, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Xiaomei Feng, Huiping Guan, Ying Kan, Stephanos Ioannidis, Bo Peng, Mei Su, Bin Wang, Tao Wang, Hai-Jun Zhang
  • NEW COMPOUNDS 835
    Publication number: 20080287460
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: May 14, 2008
    Publication date: November 20, 2008
    Applicants: Astex Therapeutics Limited, AstraZeneca AB
    Inventors: Jeremy Nicholas Burrows, Sven Hellberg, Katharina Hogdin, Sofia Karlstrom, Karin Kolmodin, Johan Lindstrom, Can Slivo
  • NEW CRYSTALLINE FORMS
    Publication number: 20080287413
    Abstract: There are provided crystalline forms of the compounds Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)-Aze-Pab(OMe) and Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)-Aze-Pab(OH), pharmaceutical compositions containing them, processes for obtaining them and their use in medical treatment.
    Type: Application
    Filed: December 5, 2007
    Publication date: November 20, 2008
    Applicant: AstraZeneca AB
    Inventors: Bengt Leonard Aslund, Stefan Bengtsson, Gudrun Anita Bergman, Ursula Renata Maria Hohlneicher, Bo Ingvar Ymen
  • Heterocyclic Inhibitors of Mek and Methods of Use Thereof
    Publication number: 20080280957
    Abstract: Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 17, 2006
    Publication date: November 13, 2008
    Applicants: ARRAY BIOPHARMA, INC., ASTRAZENECA AB
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hoog Woon Yang, James Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding